![Augustine Therapeutics Raises $18.5 Million in a Series A First Closing](https://cmtrf.org/wp-content/uploads/2023/03/Current_Augustine-Tx_35mm-Logo-1.png)
![Augustine Therapeutics Raises $18.5 Million in a Series A First Closing](https://cmtrf.org/wp-content/uploads/2023/03/Current_Augustine-Tx_35mm-Logo-1.png)
![CMT Research Foundation Invests in ReviR Therapeutics Research to Pioneer Small Molecule Therapeutics for CMT1A](https://cmtrf.org/wp-content/uploads/2024/06/ReviR-1080x512.png)
CMT Research Foundation Invests in ReviR Therapeutics Research to Pioneer Small Molecule Therapeutics for CMT1A
The CMT Research Foundation has formed a strategic partnership with ReviR Therapeutics to advance small molecule therapeutics that modulate the expression of the gene that causes CMT1A. ReviR Therapeutics is developing a class of drugs called small molecule splice...![NMD Pharma Receives FDA Clearance to Initiate Clinical Trial of NMD670 for CMT](https://cmtrf.org/wp-content/uploads/2024/04/NMD_Pharma_3-1080x327.png)
NMD Pharma Receives FDA Clearance to Initiate Clinical Trial of NMD670 for CMT
NMD Pharma recently announced that it has received clearance from the US Food and Drug Administration (FDA) for its Investigational New Drug (IND) application to initiate a Phase 2 clinical trial of NMD670 in patients living with CMT types 1 and 2. NMD670 is a...![CMTRF at the 2024 American Society of Gene and Cell Therapy Conference](https://cmtrf.org/wp-content/uploads/2024/05/ASGCT-1080x675.png)
CMTRF at the 2024 American Society of Gene and Cell Therapy Conference
We are thrilled to see that two CMTRF-funded projects were selected to present their advancements on their CMT gene therapy projects at the ASGCT conference, the premier conference for emerging genetic therapies. Dr. Lindsay Wallace presented a poster on the CMT1A...![CMT Research Foundation Invests in Project to Test if a Commercially Available Drug is Effective Treatment for X-linked Charcot-Marie-Tooth Disease](https://cmtrf.org/wp-content/uploads/2024/04/Abrams.png)
CMT Research Foundation Invests in Project to Test if a Commercially Available Drug is Effective Treatment for X-linked Charcot-Marie-Tooth Disease
The CMT Research Foundation (CMTRF), a non-profit focused solely on delivering treatments and cures for Charcot-Marie-Tooth disease (CMT), has invested in a project led by Dr. Charles Abrams, a Professor in the Department of Neurology and Rehabilitation at the...![Vanderbilt’s Charles Sanders Successfully Finds Molecules That Alter PMP22 Production or Cell Surface Trafficking; In Next Phase Will Test if They Can Improve CMT-like Problems in Schwann Cells](https://cmtrf.org/wp-content/uploads/2024/03/Dedicated-to-Research-Committed-to-a-Cure-1-1080x675.png)